Member Info for BruceJamieson

of course it is short able like all shares use the right instrument! Or better still hang on for a substantial bounce

interesting situation. FT markets show shares outstanding 62.41 m free float 40.63. But apart from BOD there are some major holdings eg Schroders 8.1%, Hargreaves Hale 4.7, River & Mercantile IT 5.3 and Old Mutual 6.2. these people are eclefts and not here for their health! very encouraging indeed.

If huge volume on Tuesday it will be too late to get back in!

Not much for those of us who,paid 220p

On high volume; I wonder why?

Surely GVC streets ahead of Wm Hill?

Are they not overdue by 2 months?

In March the following had major interests - Criseren 3.14%, Octopus ( small fund managers) 19.91% ( yes that is nineteen!), American Vanguard 15.15% and Legal & General 7.04%. These are serious players and we should take heart therefrom!!

Spread betting is on the margin short OR long. Shorts can be going short naked or covered or CFD or good old fashioned put options or many others.

half a pence???? Surely you mean half a penny!!

The local tipple is actually Montefalco Sagrantino. But yesterday I had a glass of cheap rose from a box and today an Aperol Spritz in a bar for only €3

Strange that the tech colleges teaching skills half empty. Corbyn does tell a good tale. Pity it is Trotskist clap trap. Note not Marxist/lLeninist as they do not believe in democracy whereas Trotsky did. hence why Stalin had him bumped off!

there are two classes of shares. They have different rockers and different prices

earlier today announcement that vancomycin can be modified structurally to avoid resistance re emerging. See comments by Prof BOger. There must be something in it for researchers!

There has been one new antibiotic in 30 years IE lugdunin

Sccording to Hardman & Co news letter 3.4.17 RedX is involved in Carb-X gram- negative program against MDR bacteria. They have the topoisomerase inhibitors and it is worth pointing out the Hlobal Maket for anti biotics is worth $14.5 billion annually. I do not recognise that few are in this field

Such as Axa will have something to say!

Don't forget one of very few companies developing new anti biotics

this is a splendid co. Read the Hadman report. Numerous good drugs either approved or almost then marketed by others. Surely the pundits are not wrong! SP holding up well which is all you need to know!

remember they do not do the selling themselves. That is moved on. this is much less risky than other pharmas